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structural issues and can be resolved.
The p53 resequencing microarray is
currently undergoing a redesign
(Roche Molecular Diagnostics, per-
sonal communication). Given the
cost-effectiveness of chip technology,
it is reasonable to expect a next-
generation Chip in which most of
these limitations have been ad-
dressed. Such improvements could
lead to a more useful and productive
tool in cancer research and diagnos-
tics.
References
1. Cooper M, Li S-Q, Bhardwhaj T, Rohan T, Kandel
RA. Evaluation of oligonucleotide arrays for se-
quencing of the p53 gene in DNA from formalin-
fixed, paraffin-embedded breast cancer speci-
mens. Clin Chem 2004;50:500–8.
2. Ahrendt SA, Halachmi S, Chow JT, Wu L, Hala-
machi N, Yang SC, et al. Rapid p53 sequence
analysis in primary lung cancer using an oligonu-
cleotide probe array. Proc Natl Acad Sci U S A
1999;96:7382–7.
Antonette C.P. Allen*
Francis A. Chiafari
BRT Laboratories, Inc.
400 West Franklin St.
Baltimore, MD 21201
*Author for correspondence. Fax 410-
383-0938; e-mail allen@brtlabs.com.
Previously published online at DOI:
10.1373/clinchem.2004.038158
Drs. Kandel and Rohan respond:
To the Editor:
We would like to thank Drs. Allen
and Chiafari for their comments.
They reiterate many of the points we
made in our report (1 ). We are glad
that they also had similar findings.
However, they suggest that we differ
in the detection of polymorphisms.
In the Discussion section of our re-
port (1 ), we speculated that our cut-
off score might be too high because
we observed that a polymorphism in
exon 6 had a score of 6. In their
study, the GeneChip detected one of
six exon 4 (codon 72) polymor-
phisms, whereas we were unable to
detect any in 12 cases from which we
obtained a PCR product. We would
argue that this was not a significant
difference because both sample sizes
are small. In fact, it actually supports
our conclusion that a combination of
both microarray and sequencing is
required to identify p53 alterations,
as they would have missed five poly-
morphisms. We also look forward to
being able to use the next-generation
p53 microarray, as we stated in our
report (1 ), because this methodology
definitely has a role to play in se-
quencing of the p53 gene.
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Increased Frequency of the MTHFR
A1298C Mutation in an Irish
Population
To the Editor:
The enzyme methylenetetrahydrofo-
late reductase (MTHFR) catalyzes
the reduction of methylene tetrahy-
drofolate to 5-methyltetrahydrofo-
late, the cosubstrate required for
the remethylation of homocysteine
to methionine. Mutations in the
MTHFR enzyme are reported as
causes of hyperhomocysteinemia (1 ).
Hyperhomocysteinemia is generally,
although not universally, seen as an
independent and graded risk factor
for venous thrombosis and neural
tube defects (2 ). Several polymor-
phisms have been reported in the
MTHFR gene, but two particular mu-
tations generate the most interest,
the recently described A1298C (3 )
and the most-characterized C677T
(4 ). The A1298C polymorphism in
the MTHFR gene encodes for a glu-
tamate to alanine substitution and
leads to a decrease in enzyme activ-
ity. Combined heterozygosity for the
C677T/A1298C polymorphisms in
some studies (5 ) is associated with
higher homocysteine concentrations
and decreased plasma folate.
Amplification Refractory Mutation
System (ARMS) PCR determination
of the MTHFR C677T mutation has
been described by Hessner et al. (6 ).
To determine the frequency of the
A1298C mutation in the Irish popu-
lation, we developed a reliable and
rapid ARMS PCR method. We com-
pared the results with those obtained
with the standard method for detec-
tion, PCR followed by restriction
fragment length polymorphism (RFLP)
analysis (3 ).
Our cohort consisted of 120 blood
donors, none of whom had experi-
enced any past or current thrombotic
events or had a family history of
thrombosis. Informed consent was
obtained from all study participants.
Total genomic DNA was isolated
from blood leukocytes, and MTHFR
A1298C was analyzed by PCR-RFLP
(3 ).
ARMS PCR was also used to de-
termine the frequency of this muta-
tion. A typical ARMS PCR set-up for
the wild-type reaction consisted of
200 ng of genomic DNA, 2.5 mM
MgCl2, 0.4 mM each deoxynucleo-
tide triphosphate (Invitrogen, Bio-
Sciences), 2.5 L of 10	 buffer [200
mM Tris-HCl (pH 8.4), 500 mM KCl;
Invitrogen], 1.5 U of Platinum Taq
polymerase (Invitrogen), and 50
mL/L dimethyl sulfoxide (Sigma-
Aldrich). ARMS PCR primers used
in the wild-type reaction were as
follows: A1298C forward consensus
primer (5-CCTTTGGGGAGCTGA-
AGGACTACTAC-3); A1298C wild-
type reverse primer (5-CAAAGAC-
TTCAAAGACAGTC-3); cystic fi-
brosis 22 (CF22) forward primer
(5-AAACGCTGAGCCTCACAAGA-
3), and CF22 reverse primer (5-
TGTCACCATGAAGCAGGCAT-3;
Sigma-Aldrich). The mutant reaction
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had the same components as above,
with the replacement of A1298C
wild-type reverse primer with
A1298C mutant reverse primer,
which had the following sequence:
5-GGTAAAGAACAAAGACTTCA-
AAGACACTGTG-3 (Sigma-Aldrich).
ARMS PCR conditions were 95 °C
for 5 min; 40 cycles of 95 °C for 30 s,
57 °C for 30 s, and 72 °C for 30 s; and
72 °C for 5 min. The wild-type reac-
tion produces a 120-bp product,
whereas the mutant reaction pro-
duces a 127-bp fragment (Fig. 1). The
CF22 primers were used as internal
control primers and produce a
578-bp fragment in each reaction.
Statistical analysis was performed
using the Z-test for two independent
proportions. Statistical significance
was set at Z 1.96.
Of the 120 healthy Irish partici-
pants, 56 were heterozygous car-
riers, giving a genotype frequency of
46.7%, whereas 11 (14.2%) were
homozygous for A1298C. Of the
MTHFR C677T/A1298C genotype
combinations, 28 participants (23.3%)
were double heterozygotes. The
prevalence of 1298CC homozygotes
in this Irish study is significantly
higher than that reported for most
European populations, including a
UK study (Z  1.97) (7 ), an Italian
cohort (Z  2.51) (8 ), and an Ameri-
can study (Z  1.99) (9 ). Only two
studies from Northern Scotland
(10, 11) have reported a higher prev-
alence.
The results of the ARMS PCR were
in complete concordance with the
results obtained by standard PCR-
RFLP. The ability of the ARMS PCR
to distinguish between genotypes for
the A1298C mutation is much higher
than that of the standard method.
We thank Dr. A Davern, Dublin
Blood Transfusion Centre, for the
blood samples. We would like to
also thank Drs. Valeria Capra (Labo-
ratorio del Servizio di Neurochiru-
gia, Instituto Scientifico G. Gaslin,
Genova, Italy) and Nurit Rosenberg
(Department of Hematology, Insti-
tute of Thrombosis and Hemostasis,
The Chaim Sheba Medical Center,
Tel-Hashomer, Israel) for the A1298C
positive controls.
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Interference in Measurement of
Potassium Caused by Bacterial
Contamination of an Analyzer
To the Editor:
We encountered a problem with po-
tassium measurement after periods
of standby on a Beckman Synchron
LX20 Pro. Initial potassium measure-
ments were rejected because of ex-
cessive reference drift, and potas-
sium results for quality-control (QC)
samples were as much as 2.5
mmol/L above the previous mean.
Replicate analyses of control material
immediately after standby revealed a
decreasing trend in potassium con-
centration, whereas simultaneously
Fig. 1. ARMS PCR for MTHFR
A1298C.
Reactions are shown in pairs.
Products of the wild-type reaction
are analyzed in the first lane of
each pair, products of mutant re-
action are analyzed in the second
lane of each pair. Each pair con-
tains the CF22 internal control,
which generates a 578-bp prod-
uct. Lane 0, 100-bp DNA ladder
(Invitrogen, Bio-Sciences); lanes
1 and 2, presence of the 120-bp
product in lane 1 indicates wild
type for the mutation; lanes 3 and
4, presence of 120-bp product in
lane 3 and 127-bp product in lane
4 indicate heterozygous carrier of
the mutation; lanes 5 and 6, pres-
ence of the 127-bp product in
lane 6 indicates a homozygous
carrier of the mutation.
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